# Biostatistics Shared Resource

> **NIH NIH P30** · MEDICAL UNIVERSITY OF SOUTH CAROLINA · 2024 · $248,958

## Abstract

BIOSTATISTICS SHARED RESOURCE (BSR): SUMMARY
The mission of the Biostatistics Shared Resource (BSR) is to provide the Hollings Cancer Center (HCC)
exceptional and state-of-the-art biostatistics support, team-focused collaboration, consulting, and educational
training and mentorship that is cost-effective, accessible, and responsive. Under the leadership of Elizabeth
Hill, PhD (CBI), BSR is comprised of highly qualified biostatisticians with rigorous statistical training and
complementary expertise in statistical methods relevant to cancer research. Hill has extensive expertise in
basic, translational, clinical, and population cancer research, and over 15 years of service to HCC in
collaborative, educational, and leadership roles. BSR expertise includes methods in early phase clinical trials,
cluster-randomized trials, biomarker discovery, spatial and spatiotemporal statistical methods, longitudinal data
analysis, Bayesian statistical methods, hierarchical and multi-level models, latent class and latent trait models,
and bioinformatics tool development for single-cell imaging platforms and multi-omics applications. A critical
operational feature of BSR is early involvement in study design, followed by an integrated approach with HCC
members in grant writing, data analysis, and manuscript preparation. Direct participation of BSR personnel in
monthly Program meetings, transdisciplinary cancer team meetings, and BSR-led training and mentorship
activities, enhances the quality, rigor, and reproducibility of HCC members’ research. During the current cycle,
BSR launched a major initiative in data standardization based on NIH Common Data Elements (CDEs). In
partnership with the HCC Clinical Trials Office, BSR now oversees the construction of all electronic case report
forms and databases using NCI-preferred standards and NIH-endorsed CDEs. BSR personnel have partnered
with HCC members in all research Programs and were instrumental in: demonstrating improvement in body
image disturbance in head and neck cancer survivors, leading to a confirmatory multi-site randomized
controlled trial using a novel partially clustered design (Evan Graboyes, MD (CC) R01 CA269385); opening to
accrual MUSC’s first cellular therapy investigator-initiated clinical trial, a dose-escalation and dose-expansion
trial evaluating the safety of a CD19-CD34t metabolically fit CAR T-cell therapy in adult patients with non-
Hodgkin lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma (Brian Hess, MD (DCT),
and Shikhar Mehrotra, PhD (DCT), NCT05702853); and establishing a program to better understand the
underlying mechanisms of cachexia in patients with pancreatic ductal adenocarcinoma (Denis Guttridge, PhD
(CBI), P01 CA236778). With HCC support, committed leadership, and exceptional personnel, BSR is poised to
support emerging challenges and opportunities in cancer research.

## Key facts

- **NIH application ID:** 10847777
- **Project number:** 2P30CA138313-16
- **Recipient organization:** MEDICAL UNIVERSITY OF SOUTH CAROLINA
- **Principal Investigator:** Elizabeth G. Hill
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $248,958
- **Award type:** 2
- **Project period:** 2009-04-01 → 2029-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10847777

## Citation

> US National Institutes of Health, RePORTER application 10847777, Biostatistics Shared Resource (2P30CA138313-16). Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/grant/nih/10847777. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*